Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Net Cash Flow (2025)

Drugs Made In America Acquisition filings provide 1 years of Net Cash Flow readings, the most recent being $5420.0 for Q4 2025.

  • Quarterly Net Cash Flow changed N/A to $5420.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4786.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $4786.0 for FY2025, 254.26% up from the prior year.
  • Net Cash Flow hit $5420.0 in Q4 2025 for Drugs Made In America Acquisition, up from -$105.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $5420.0 in Q4 2025 and bottomed at -$428.0 in Q1 2025.